Evaluation of Beta vulgaris total extract effect on improvment of non-alcoholic fatty live disease factors

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121017011145N20

Enrollment

120

Registered

2018-05-18

Start date

2018-02-20

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non – alcoholic fatty live disease. Other specified inflammatory liver diseases

Interventions

Intervention 1: Intervention group: Beta-vulgaris extract capsule 400 mg daily (Institute of Medicinal Plants, Iran) for 6 months. Intervention 2: Control group: Placebo capsule daily (Institute of Me

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ?Age 18-70 years old Non-alcoholic fatty live disease diagnosis

Exclusion criteria

Exclusion criteria: Pregnancy and lactation alcohol consumption Drug addiction Diabetes mellitus, cirrhosis, hepatitis

Design outcomes

Primary

Measure	Time frame
Liver aminotransferases. Timepoint: Before starting treatment, three and six months after starting treatment. Method of measurement: ELISA test.;The severity of fatty liver. Timepoint: Before starting treatment, three and six months after starting treatment. Method of measurement: Liver ultrasound.	—

Secondary

Measure	Time frame
Fasting Blood Glucose, Triglycerides, and Cholesterol. Timepoint: Before the intervention, three and six months after the intervention. Method of measurement: Biochemical laboratory tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHasan Afzali

Kashan University of Medical Sciences

hasanafsali@yahoo.com+98 31 5554 0026

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026